{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:06:37Z","timestamp":1769839597837,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016061","name":"Stichting de Drie Lichten","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2022\/GNT2018514"],"award-info":[{"award-number":["2022\/GNT2018514"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neoadjuvant systemic therapy (NAST) for patients with stage III melanoma achieves high major pathologic response rates and high recurrence-free survival rates. This study aimed to determine how NAST with targeted therapies (TTs) and immune checkpoint inhibitors (ICIs) influences surgical outcomes after lymph node dissection in terms of complications, morbidity, and textbook outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients who underwent a lymph node dissection after either NAST in a clinical trial or upfront surgery for stage III melanoma between 2014 and 2022 were identified from an institutional research database.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study included 89 NAST-treated patients and 79 upfront surgery-treated patients. The rate of postoperative complications did not differ between the NAST- and upfront surgery-treated patients (55% vs. 51%; <jats:italic>p<\/jats:italic>\u2009=\u20090.643), and steroid treatment for drug toxicity did not influence the complication rate (odds ratio [OR], 1.1; 95% confidence interval [CI], 0.4\u20133; <jats:italic>p<\/jats:italic>\u2009=\u20090.826). No significant differences in postoperative morbidity were observed in terms of seroma (23% vs. 11%; <jats:italic>p<\/jats:italic>\u2009=\u20090.570) or lymphedema (36% vs. 51%; <jats:italic>p<\/jats:italic>\u2009=\u20090.550). The rate of achieving\u00a0a textbook outcome was comparable for the two groups (61% vs. 57%; <jats:italic>p<\/jats:italic>\u2009=\u20090.641).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The surgical outcomes after lymph node dissections were comparable between the patients who received NAST and those who had upfront surgery, indicating that surgery can be safely performed after NAST with TT or ICI for stage III melanoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-024-15274-0","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T19:01:41Z","timestamp":1716058901000},"page":"5324-5330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort"],"prefix":"10.1245","volume":"31","author":[{"given":"Lisanne P.","family":"Zijlker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Spillane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serigne N.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Rawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Colebatch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan R.","family":"Stretch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sydney","family":"Ch\u2019ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omgo","family":"Nieweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerwin F.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn P. M.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander C. J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"key":"15274_CR1","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","volume":"383","author":"R Dummer","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2020;383:1139\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2005493.","journal-title":"N Engl J Med"},{"key":"15274_CR2","doi-asserted-by":"publisher","first-page":"EVIDoa2200214","DOI":"10.1056\/EVIDoa2200214","volume":"1","author":"AMM Eggermont","year":"2022","unstructured":"Eggermont AMM, Kicinski M, Blank CU, et al. Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma. NEJM Evid. 2022;1:EVIDoa2200214. https:\/\/doi.org\/10.1056\/EVIDoa2200214.","journal-title":"NEJM Evid"},{"key":"15274_CR3","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","volume":"29","author":"J Larkin","year":"2023","unstructured":"Larkin J, Del Vecchio M, Mandala M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin Cancer Res. 2023;29:3352\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3145.","journal-title":"Clin Cancer Res"},{"key":"15274_CR4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","volume":"27","author":"EA Rozeman","year":"2021","unstructured":"Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021;27:256\u201363. https:\/\/doi.org\/10.1038\/s41591-020-01211-7.","journal-title":"Nat Med"},{"key":"15274_CR5","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.Cd-16-0577","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu J, Blake SJ, Yong MCR, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6:1382\u201399. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0577.","journal-title":"Cancer Discov"},{"key":"15274_CR6","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24:1655\u201361. https:\/\/doi.org\/10.1038\/s41591-018-0198-0.","journal-title":"Nat Med"},{"key":"15274_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","volume":"34","author":"JM Versluis","year":"2023","unstructured":"Versluis JM, Menzies AM, Sikorska K, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol. 2023;34:420\u201330. https:\/\/doi.org\/10.1016\/j.annonc.2023.01.004.","journal-title":"Ann Oncol"},{"key":"15274_CR8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388:813\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2211437.","journal-title":"N Engl J Med"},{"key":"15274_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","volume":"611","author":"RN Amaria","year":"2022","unstructured":"Amaria RN, Postow M, Burton EM, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022;611:155\u201360. https:\/\/doi.org\/10.1038\/s41586-022-05368-8.","journal-title":"Nature"},{"issue":"16 Suppl","key":"15274_CR10","doi-asserted-by":"publisher","first-page":"9580","DOI":"10.1200\/JCO.2022.40.16_suppl.9580","volume":"40","author":"AM Menzies","year":"2022","unstructured":"Menzies AM, Saw RPM, Lo SN, et al. Neoadjuvant dabrafenib and trametinib (D\u2009+\u2009T) for stage III melanoma: long-term results from the NeoCombi trial. J Clin Oncol. 2022;40(16 Suppl):9580\u20139580. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9580.","journal-title":"J Clin Oncol"},{"key":"15274_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","volume":"27","author":"AM Menzies","year":"2021","unstructured":"Menzies AM, Amaria RN, Rozeman EA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021;27:301\u20139. https:\/\/doi.org\/10.1038\/s41591-020-01188-3.","journal-title":"Nat Med"},{"key":"15274_CR12","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1245\/s10434-021-11236-y","volume":"29","author":"ACJ van Akkooi","year":"2022","unstructured":"van Akkooi ACJ, Hieken TJ, Burton EM, et al. Neoadjuvant systemic therapy (NAST) in patients with melanoma: surgical considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol. 2022;29:3694. https:\/\/doi.org\/10.1245\/s10434-021-11236-y.","journal-title":"Ann Surg Oncol"},{"key":"15274_CR13","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","volume":"29","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff MT, Messina JL, Stein JE, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018;29:1861\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdy226.","journal-title":"Ann Oncol"},{"key":"15274_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejca.2023.03.003","volume":"185","author":"LP Zijlker","year":"2023","unstructured":"Zijlker LP, van der Burg SJC, Blank CU, et al. Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery. Eur J Cancer. 2023;185:131\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2023.03.003.","journal-title":"Eur J Cancer"},{"key":"15274_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1097\/sla.0000000000002388","volume":"266","author":"EG Karthaus","year":"2017","unstructured":"Karthaus EG, Lijftogt N, Busweiler LAD, et al. Textbook outcome: a composite measure for quality of elective aneurysm surgery. Ann Surg. 2017;266:898\u2013904. https:\/\/doi.org\/10.1097\/sla.0000000000002388.","journal-title":"Ann Surg"},{"key":"15274_CR16","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/bjs.10486","volume":"104","author":"LA Busweiler","year":"2017","unstructured":"Busweiler LA, Schouwenburg MG, van Berge Henegouwen MI, et al. Textbook outcome as a composite measure in oesophagogastric cancer surgery. Br J Surg. 2017;104:742\u201350. https:\/\/doi.org\/10.1002\/bjs.10486.","journal-title":"Br J Surg"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15274-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15274-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15274-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T21:06:47Z","timestamp":1720645607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15274-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["15274"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15274-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,18]]},"assertion":[{"value":"7 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Alexander M. Menzies has served on an advisory board for BMS, MSD, Novartis, Roche, Pierre-Fabre, and QBiotics. John F. Thompson has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK, and Provectus Biopharmaceuticals Inc, and travel and conference support from GSK, Provectus Inc, and Novartis. Richard A. Scolyer has received fees for professional services from MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, and GlaxoSmithKline. Robyn P. M. Sawhas received honoraria for advisory board participation from MSD, Novartis, and Qbiotics, and speaking honoraria from BMS and Novartis. Robert V. Rawson has received honoraria for speaking and advisory board participation from Merck Sharp & Dohme. Georgina V. Long is consultant advisor for Agenus, Amgen, Array Biopharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Evaxion, Hexal AG (Sandoz Company), Highlight Therapeutics S.L., Innovent Biologics USA, Merck Sharpe & Dohme, Novartis, PHMR Ltd, Pierre Fabre, Provectus, Qbiotics, and Regeneron. Alexander C. J. van Akkooi declares advisory board and consultancy honoraria at Amgen, Bristol-Myers Squibb, MSD-Merck, Merck-Pfizer, Neracare, Novartis, Pierre Fabre, Sanofi, and Sirius Medical, 4SC, and research grants from Amgen and Merck-Pfizer. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}